Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
envafolimab + lenvatinib + gemcitabine + cisplatin
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University
- Modality
- Small Molecules, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Oral, Intravenous
01
Overview
This combination regimen consists of envafolimab, a subcutaneous PD-L1 single-domain antibody, lenvatinib, an oral multi-kinase inhibitor, and the chemotherapy doublet gemcitabine and cisplatin. It is being evaluated as a first-line treatment for patients with advanced biliary tract cancer (BTC). Envafolimab blocks the interaction between PD-L1 and PD-1, enhancing T-cell anti-tumor activity. Lenvatinib inhibits multiple receptor tyrosine kinases involved in angiogenesis and tumor proliferation, including VEGFR and FGFR. Gemcitabine and cisplatin provide cytotoxic effects by interfering with DNA synthesis and repair. The regimen is currently being studied in the Phase 2 ENLIGHTEN trial (NCT05410197) led by Sun Yat-sen University.
- Brand names
- EnweidaLenvima
- Other names
- EnvafolimabLenvatinibGemcitabineCisplatinGemCis
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on envafolimab + lenvatinib + gemcitabine + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on envafolimab + lenvatinib + gemcitabine + cisplatin.